559
Participants
Start Date
April 4, 2014
Primary Completion Date
August 17, 2016
Study Completion Date
August 17, 2016
adalimumab 40 mg
SC injections
sirukumab 100 mg
SC injections
sirukumab 50 mg
SC injections
Placebo
SC injections
Birmingham
Phoenix
Arvin
El Cajon
Huntington Beach
Pleasanton
Thousand Oaks
Tustin
Whittier
Newark
Aventura
Dunedin
Miami
New Port Richey
Palm Harbor
Plantation
Tampa
Kansas City
Elizabethtown
Paducah
Frederick
Wheaton
St Louis
Las Vegas
Salisbury
Wilmington
Dayton
Portland
Duncansville
Wexford
Wyomissing
Jackson
Nashville
Austin
Carrollton
Corpus Christi
Cypress
Lubbock
McKinney
Mesquite
Chesapeake
Clarksburg
Rousse
Sofia
Port Montt
Temuco
Barranquilla
Bogotá
Bucaramanga
Bad Doberan
Berlin
Cologne
Ratingen
Vogelsang-Gommern
Debrecen
Gödöllő
Klaipėda
Šiauliai
Vilnius
Chihuahua City
Guadalajara
Jalisco
Mexicali
Chisinau
Bydgoszcz
Bytom
Krakow
Lublin
Nadarzyn
Poznan
Warsaw
Wroclaw
Bucharest
Constanța
Ploieşti
Arkhangelsk
Kazan'
Kemerovo
Kursk
Moscow
Novosibirsk
Petrozavodsk
Ryazan
Saint Petersburg
Tomsk
Tver'
Vladimir
Yaroslavl
Belgrade
Novi Sad
Zemun
Cape Town
Durban
Kempton Park
Stellenbosch
A Coruña
Madrid
Chernihiv
Kryvyi Rih
Kyiv
Lviv
Odesa
Poltava
Sumy
Ternopil
Vinnytsia
Zaporizhzhia
Collaborators (1)
GlaxoSmithKline
INDUSTRY
Janssen Research & Development, LLC
INDUSTRY